Targeting CDK6 and BCL2 exploits the “MYB addiction” of Ph+ acute lymphoblastic leukemia

Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is currently treated with BCR-ABL1 tyrosine kinase inhibitors (TKI) in combination with chemotherapy. However, most patients develop resistance to TKI through BCR-ABL1-dependent and -independent mechanisms. Newly developed TKI c...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Res
Auteurs principaux: De Dominici, Marco, Porazzi, Patrizia, Soliera, Angela Rachele, Mariani, Samanta A., Addya, Sankar, Fortina, Paolo, Peterson, Luke F., Spinelli, Orietta, Rambaldi, Alessandro, Martinelli, Giovanni, Ferrari, Anna, Iacobucci, Ilaria, Calabretta, Bruno
Format: Artigo
Langue:Inglês
Publié: 2017
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5815914/
https://ncbi.nlm.nih.gov/pubmed/29233926
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-17-2644
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires